Barinthus Biotherapeutics
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing innovative T cell immunotherapeutics for chronic infectious diseases, autoimmunity, and cancer, with offices in the UK and the US.
Services
Barinthus Biotherapeutics focuses on developing T cell immunotherapeutics designed to guide the immune system to combat chronic infectious diseases, autoimmunity, and cancer. The company provides innovative solutions through its pipeline, which includes various therapeutic and prophylactic products targeting diseases like HBV, HPV, celiac disease, prostate cancer, NSCLC, MERS-CoV, and shingles. Their approach aims to create more effective immunotherapies by leveraging their suite of proprietary technologies.
Products
Barinthus Biotherapeutics has a diverse range of products in development. Key candidates include VTP-300 for chronic HBV infection, VTP-200 for high-risk HPV infections, VTP-850 for prostate cancer, VTP-1000 for celiac disease, and VTP-600 targeting MAGE-A3 and NY-ESO-1 antigens for NSCLC. Additionally, the company is working on VTP-500, a prophylactic vaccine for MERS-CoV, and VTP-400, a next-generation shingles prophylactic product.
Proprietary Platforms
Barinthus Biotherapeutics' innovative research is driven by its four proprietary platform technologies: ChAdOx, MVA, SNAP-TI, and SNAP-CI. These platforms serve as the foundation for their product development pipeline and are designed to create more effective and targeted immunotherapies for treating infectious diseases, cancer, and autoimmune conditions.
Global Partnerships
Barinthus Biotherapeutics has developed strategic partnerships with leading global institutions to enhance their research and development efforts. These collaborations include partnerships with CanSino Biologics Inc., Cancer Research UK, the University of Oxford, Enara Bio, Ludwig Cancer Research, OXGENE, and Oxford University Innovation. These partnerships support the advancement of Barinthus Biotherapeutics' innovative immunotherapy products.
Locations
Barinthus Biotherapeutics operates out of two main offices, one located in Harwell, UK, and the other in Germantown, Maryland, USA. These locations support the company's efforts in research, development, and clinical studies, contributing to their mission of pioneering novel immunotherapeutics.